Publications by authors named "Fu Siqing"

Claim this Profile
P
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion.
Sarina A Piha-Paul, Chieh Tseng, Emily Thompson, R Jason Stafford, Hung Le, Siqing Fu

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers.
Steven H Lin, Vivek Subbiah, Shinya Neri, Evan N Cohen, Ziyi Li, Siqing Fu

Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.
Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, Ecaterina E Dumbrava, David S Hong

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.
Camila Braganca Xavier, Clark R Andersen, JoAnn Lim, Julian H Slade, Stacie A Bean, Siqing Fu

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Yuxiang Ma, Yunpeng Yang, Yan Huang, Wenfeng Fang, Jinhui Xue, Siqing Fu

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim, Siqing Fu

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic, Siqing Fu

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik, Siqing Fu

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz, Siqing Fu

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Erika P Hamilton, Gerald S Falchook, Judy S Wang, Siqing Fu, Amit M Oza

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Siqing Fu

JCO Precis Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic extraneural glioblastoma diagnosed with molecular testing.
Nazanin K Majd, Henry Hiep Vo, Cesar A Moran, Shiao-Pei Weathers, I-Wen Song, Siqing Fu

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp, Siqing Fu

NPJ Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
Chad Tang, Genevieve P Hartley, Coline Couillault, Ying Yuan, Heather Lin, Siqing Fu

BMJ Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Anne Knisely, Jibran Ahmed, Bettzy Stephen, Sarina A Piha-Paul, Daniel Karp, Siqing Fu

Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia M Tsimberidou, Filip Janku, Siqing Fu

Cancer Res Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Role of Synthetic Lethality in -Deficient Malignancies.
Kyaw Z Hein, Bettzy Stephen, Siqing Fu

J Immunother Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah

Oncologist· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q Rizvi, Siqing Fu

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Siqing Fu

Cancer Chemother Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Bettzy Stephen, Joud Hajjar, Shrutii Sarda, Dzifa Yawa Duose, Jeffrey M Conroy, Siqing Fu

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, Siqing Fu

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Siqing Fu

NPJ Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis